Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright

Investment analysts at HC Wainwright assumed coverage on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued on Monday, Benzinga reports. The firm set a “buy” rating and a $18.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 181.25% from the company’s current price.

Several other analysts also recently commented on the company. Rodman & Renshaw began coverage on Coya Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $18.00 target price on the stock. Chardan Capital reiterated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, June 5th.

Coya Therapeutics Stock Up 7.4 %

Coya Therapeutics stock opened at $6.40 on Monday. The company has a market capitalization of $93.56 million, a P/E ratio of -7.53 and a beta of 0.58. The stock’s 50 day moving average is $6.34 and its 200 day moving average is $7.60. Coya Therapeutics has a twelve month low of $3.21 and a twelve month high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $3.43 million during the quarter. As a group, equities analysts expect that Coya Therapeutics will post -1.17 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after buying an additional 750,338 shares during the period. Greenlight Capital Inc. lifted its holdings in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after buying an additional 805,959 shares during the period. AIGH Capital Management LLC lifted its holdings in shares of Coya Therapeutics by 92.6% during the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after buying an additional 496,183 shares during the period. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics during the 2nd quarter valued at $61,000. Finally, Renaissance Technologies LLC bought a new position in shares of Coya Therapeutics during the 2nd quarter valued at $101,000. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.